Dr Davenport

Endocrinologist in Connolly Hospital Blanchardstown. Interested in the disease of obesity. Tweets a mix of professional and personal.

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Worldwide, approximately half of the general population is actively attempting to lose weight. However, weight loss is typically followed by substantial weight regain, often leading to repeated cycles of loss and gain of bodyweight https://t.co/6vqmVu0nfO
#obesity #weightloss

[EASO @EASOobesity]

Prof. Sadaf Farooqi, winner of the EASO-@novonordiskfond Obesity Prize for Excellence, has shown that single gene defects can cause severe obesity. By proving the biological basis of eating behaviour, her work helps address biases and fosters compassion.

https://t.co/9kEBuAoCr9

[Frontline Gastro @FrontGastro_BMJ]

🚨 New in Frontline Gastroenterology

Are GLP-1 receptor agonists safe and effective in patients with IBD?

This systematic review & meta-analysis of 23 studies including >150,000 patients found GLP-1 RAs were associated with:

⬇️ BMI
⬇️ IBD-related surgery
⬇️ IBD-related hospitalisation
✅ No signal of IBD worsening

GI adverse effects remain important, with discontinuation reported in 11–24% of patients.

An important and timely synthesis as obesity and metabolic disease become increasingly relevant in IBD care.

🔗 https://t.co/y4TofrJktM

@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro

[EASO @EASOobesity]

Asthma & Obesity

New research presented at #ECO2026 shows the use of the new GLP-1 class of obesity drugs by people with asthma is associated with a 26% fall in the number of asthma exacerbations & a 14% drop in use of asthma inhaler relievers.

https://t.co/4Yuj4DRLbK

[Dr Davenport @DrCDav]

#cullenout

[Jen Can NuSH @JCanNuSH]

🚨TRIUMPH-1 results are out.

Treatment regimen estimand for 12mg 25% at 80 weeks. In the extension that went to 104 weeks with just those of BMI > 35, it was 29.9% (efficacy estimand 30.3%).

The efficacy estimand was 19% for 4mg (treatment regimen estimand of 17.6%) with just one titration step.

Discontinuation due to adverse events were 4.1-11.3% depending on the dose.

Dysesthesia topped out at 12.5% (vs semaglutide 7.2mg’s 22%).

$LLY

[Joe Zucchi, PA-C, CPT @JPZfitness]

Several major ECO updates in obesity medicine: Zepbound maintenance data, oral Foundayo as a possible maintenance option, high-dose Wegovy 7.2 mg and oral Wegovy high responders, and encouraging body composition data. Big theme: long-term, individualized treatment is the future.

[Dr Davenport @DrCDav]

#slotout PLEASE!!!!

[ABCD Diabetes @ABCDiab]

A new multidisciplinary consensus statement has been published on the elective peri-operative management of adults taking GLP-1 receptor agonists, GIP agonists and SGLT2 inhibitors.

Read the statement ▶️ https://t.co/xPSOidVWUw

[ObesitySEEN @ObesitySeen]

📉💉 Los agonistas GLP-1 y la tirzepatida favorecen principalmente la pérdida de grasa, con preservación relativa de masa muscular.

📚 Nueva revisión sistemática en International Journal of Obesity.

https://t.co/LDn5LFYk0y

[Vincent Rajkumar @VincentRK]

Here is the inside story on how @UpToDate does what it does.

From my experience as an author/section editor for UpToDate for 20 years, here is how it works. It’s amazing!

Every day a team of people @UpToDate scour the top medical journals (and major meeting abstracts) for articles of importance. In my case they pertain to myeloma and related disorders. Any article that is felt to be important is sent to a expert MD medical editor at UpToDate who reviews the paper. If the information is felt to be important, the relevant chapter is updated with this content, summarized in a few sentences in Word track and then sent to the author of the chapter who is a top expert in the field.

As an author I have to review the update in detail and then make a decision whether to include the new information, and whether the way it has been incorporated is correct or needs to be edited.

Once I make a decision, it is then reviewed by an expert section editor. For 15 years for me, the section editor was Dr. Robert Kyle! (Currently I’m the section editor and we have about 6 experts serve as authors on over 40 chapters pertaining to myeloma and related disorders). The section editor independently decides whether the author made the right call and either approves or we have a back and forth till we agree.

The updated chapter is then reviewed again by the expert MD editor at UpToDate and then posted.

For important phase III trials or FDA approvals we usually make the update within a week. Sometimes by the next day! With so many important papers, every week there are 2-3 updates pertaining to my chapters that go through the above process! It’s hard work but it keeps me ridiculously current. And more importantly it keeps the content accurate and current. This is not random addition of new information. It’s vetted information that’s added.

Every UpToDate chapter is also peer reviewed annually. Each chapter also undergoes an annual author and editor review to make sure that the overall content and flow is good and to delete content that may be no longer important or accurate. The extraordinary process and rigor involved is why it’s such an invaluable irreplaceable resource. It is AMAZING and hard to replicate.

UpToDate is easy to navigate. But the newly launched UpToDate Expert AI takes it to the next level! It makes the entire content available to query just like you query a top ranked LLM. But it’s not searching the random internet or a stack of published articles. It’s primarily trained and derives vetted and adjudicated UpToDate content. It will not randomly hallucinate. It will not list 10 options for treatment newly diagnosed myeloma but will give you what experts currently feel is the best option based on the latest evidence. All answers are referenced and pointing to specific content sections in UpToDate (which also has links to source material). So you can immediately get all the background information if you need more detail.

Working with UpToDate has helped my career immensely. For the last 20 years it has been impossible for me to not know about every important study related to myeloma and related disorders as they get published! For 20 years, I have received a precise summary of every important article published in my field. More importantly I am forced to read them, review the source material, and make a judgment call. As a result I remember this stuff. A gift indeed!

[Dr Davenport @DrCDav]

Rubbish finish to a great game. I would be furious if I had been in the grounds. #ULSvSTO

[NICE @NICEComms]

New recommendation: Semaglutide (Wegovy) can now be prescribed to help protect the heart, not just to manage weight: https://t.co/BH4w1kI4So

It's for adults who've already had a heart attack, stroke, or cardiovascular event and have a BMI of 27 or above.

[Katherine Argent @effthealgorithm]

Search is full of ads and wrong answers. Every other email is an ad. Prime Video charges you and shows ads. Paramount? Ads. Peacock? YouTube? Hulu? Ads followed by more ads. Netflix full of ads. Meta and X, every other thing is an ad. Pinterest is nothing but ads. AI is in everything. AI finishes sentences incorrectly and won’t stop. AI reads your email and search history to target you with more ads. Every time you open an app or visit a site there’s an update making it worse. In a hurry? First, click here to agree to terms you don’t have time to read and must accept. You need an account to do that. Change your temporary password. Enter your 2FA code. Check your email and enter that code. Now use a passkey. Your password is too simple to remember. Change it. No, not like that. Now log on. Enter your 2FA code. Check your email for a code… Welcome back! We’ve updated our terms of service and privacy policy (you have none). Subscribe to the site. Subscribe to Netflix. Subscribe to toilet paper. Subscribe to these groceries. Pay a membership fee for the right to subscribe then tip your driver who delivers the subscriptions your membership lets you subscribe to. Time to work? We’ve got to update your laptop and will slow down everything you do until you agree to update. But first, click here to agree. Update installed — your laptop’s broken now. It doesn’t matter, since your boss just replaced you with AI. Go to your phone to complain on social media. Wait, your phone needs an update so we can add more AI. Click here. Oh sorry, your phone can’t handle this update. Now it’s useless. Go get the newest phone. Here’s a text from a friend, an email, a voice mail they left three days ago but you didn’t see until now because of sync problems with the cloud. It’s their GoFundMe. Their MLM. Their Patreon. Never mind, you didn’t respond to their text within 9 minutes and now you’re no longer friends. They blocked you. Make new friends. Download this app to find people in your area. In your neighborhood. On your street. Two doors down from you. Do you know this person yet, we think you’d get along. You need an account to use this app. That username is taken. Enter a password. Not that one, you used it on another site. You need to be connected to WiFi to download the app. Allow the app to connect to other devices on your network. Allow the app to access your contacts, know your precise location, store your credit card details. Oops, sorry, we got hacked now all that info is available on the web. There’s a class action suit. You can join. It’ll take a decade to get your $3.73 share of the ten billion settlement. We’ll send it via PayPal or deposit it to your bank, just tell us those details. Oh no, another hack. That info is circulating now, too. Here’s a spam call, a spam email, a spam text. Why are you angry? Why are you talking about getting rid of your phone? Why don’t you like AI, it lets us make all of this easier? Do you know how ridiculous that sounds? This is progress. You’ll be left behind. Do you want to be left behind? Do you???

[Daniel J Drucker @DanielJDrucker]

Beyond real world data, information from randomised placebo-controlled trials with semaglutide and liraglutide do not show an increased incidence of NAION in participants receiving GLP-1RA medicines https://t.co/Tzpb0gPQos

[BUCHANAN: Dublin Time Machine @RobLooseCannon]

Check out this satellite map of Dublin from 1966! Yep that's right,
on 19 February 1966, a KH-7 GAMBIT reconnaissance satellite operated by the CIA passed over Dublin. This magic window on our city just before things went international. You can zoom in to surprising detail. Go fullscreen then use the transparency slider at the bottom right so you can compare now with 66'!

KH-7s primary purpose was Cold War espionage against Soviet and Chinese nuclear and missile installations. This slice of swinging Dublin was used to calibrate. Mad what I find lying around the Dublin Time Machines magic drawers. The photo below is just a screenshot, you've to click the link

https://t.co/WHToxvbkoO

[Dr Davenport @DrCDav]

Please please please #slotout

[Michael Mindrum, MD @MichaelMindrum]

📢 SURMOUNT-5 post-hoc (le Roux CW et al., DOM 2026) tested WHtR <0.53 and BMI <27 kg/m² as treat-to-target thresholds in tirzepatide vs semaglutide.

📊 WHtR <0.53 achieved by 23–34% on tirzepatide vs 14–21% on semaglutide
🟢 77% who reached WHtR <0.53 achieved cardiometabolic low disease activity/remission
📈 OR 2.31 (p<0.001) for disease remission when WHtR target reached
🔴 BMI <27 threshold: NOT associated with meaningful functional outcomes
✅ WHtR is the better target based on this study.

Obesity medicine needs treat-to-target thinking. Waist-to-height ratio <0.53 is clinically predictive. BMI alone wasn't enough.

🏁 https://t.co/At9BlBuCJC

[Prof Chris P Gale @cpgale3]

Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events in adults with established cardiovascular disease &amp; BMI ≥27 kg/m2. https://t.co/UzCWtpuNUl

[Daniel J Drucker @DanielJDrucker]

While waiting for FOCUS, analysis of a matched real world TriNetX cohort of 350,536 patients with #T2D and #CVD followed for up to 5 years revealed reduced rates of legal blindness https://t.co/xMx7AkLPva